KODIAK SCIENCES INC. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
KODIAK SCIENCES INC. (KOD) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2023-03-28
- KODIAK SCIENCES INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-12-31 was $0.00.
- KODIAK SCIENCES INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-09-30 was $0.00.
- KODIAK SCIENCES INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-12-31 was $0.00.
- KODIAK SCIENCES INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-09-30 was $0.00.
- KODIAK SCIENCES INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2022 was $0.00.
- KODIAK SCIENCES INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2021 was $0.00.
- KODIAK SCIENCES INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2020 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 10-K · filed 2023-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 | $0.00 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |